Literature DB >> 26520661

1,3-Disubstituted and 1,3,3-trisubstituted adamantyl-ureas with isoxazole as soluble epoxide hydrolase inhibitors.

Vladimir Burmistrov1, Christophe Morisseau2, Dmitry Danilov3, Todd R Harris2, Igor Dalinger4, Irina Vatsadze4, Tatiana Shkineva4, Gennady M Butov3, Bruce D Hammock5.   

Abstract

Adamantyl ureas are good soluble epoxide hydrolase (sEH) inhibitors; however they have limited solubility and rapid metabolism, thus limiting their usefulness in some therapeutic indications. Herein, we test the hypothesis that nodal substitution on the adamantane will help solubilize and stabilize the compounds. A series of compounds containing adamantane derivatives and isoxazole functional groups were developed. Overall, the presence of methyl on the nodal positions of adamantane yields higher water solubility than previously reported urea-based sEH inhibitors while maintaining high inhibition potency. However, it did not improve microsomal stability.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adamantane; Inhibitor; Isocyanate; Isoxazole; Soluble epoxide hydrolase; Urea

Mesh:

Substances:

Year:  2015        PMID: 26520661      PMCID: PMC4654407          DOI: 10.1016/j.bmcl.2015.10.066

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  31 in total

1.  An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension.

Authors:  John D Imig; Xueying Zhao; Constantine Z Zaharis; Jeffrey J Olearczyk; David M Pollock; John W Newman; In-Hae Kim; Takaho Watanabe; Bruce D Hammock
Journal:  Hypertension       Date:  2005-09-12       Impact factor: 10.190

2.  Fluorescent substrates for soluble epoxide hydrolase and application to inhibition studies.

Authors:  Paul D Jones; Nicola M Wolf; Christophe Morisseau; Paul Whetstone; Bertold Hock; Bruce D Hammock
Journal:  Anal Biochem       Date:  2005-08-01       Impact factor: 3.365

3.  Soluble epoxide hydrolase is a therapeutic target for acute inflammation.

Authors:  Kara R Schmelzer; Lukas Kubala; John W Newman; In-Hae Kim; Jason P Eiserich; Bruce D Hammock
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-30       Impact factor: 11.205

4.  Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility.

Authors:  In-Hae Kim; Fenton R Heirtzler; Christophe Morisseau; Kosuke Nishi; Hsing-Ju Tsai; Bruce D Hammock
Journal:  J Med Chem       Date:  2005-05-19       Impact factor: 7.446

5.  Epoxyeicosatrienoic acids regulate Trp channel dependent Ca2+ signaling and hyperpolarization in endothelial cells.

Authors:  Ingrid Fleming; Alexandra Rueben; Rüdiger Popp; Beate Fisslthaler; Susanne Schrodt; Anna Sander; Judith Haendeler; John R Falck; Christophe Morisseau; Bruce D Hammock; Rudi Busse
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-09-13       Impact factor: 8.311

6.  1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokinetic properties.

Authors:  In-Hae Kim; Hsing-Ju Tsai; Kosuke Nishi; Takeo Kasagami; Christophe Morisseau; Bruce D Hammock
Journal:  J Med Chem       Date:  2007-09-26       Impact factor: 7.446

7.  Pyrrolidine amides of pyrazolodihydropyrimidines as potent and selective KV1.5 blockers.

Authors:  John Lloyd; Heather J Finlay; Wayne Vacarro; Tram Hyunh; Alexander Kover; Rao Bhandaru; Lin Yan; Karnail Atwal; Mary Lee Conder; Tonya Jenkins-West; Hong Shi; Christine Huang; Danshi Li; Huabin Sun; Paul Levesque
Journal:  Bioorg Med Chem Lett       Date:  2010-01-04       Impact factor: 2.823

8.  Soluble epoxide hydrolase inhibitors reduce the development of atherosclerosis in apolipoprotein e-knockout mouse model.

Authors:  Arzu Ulu; Benjamin B Davis; Hsing-Ju Tsai; In-Hae Kim; Christophe Morisseau; Bora Inceoglu; Oliver Fiehn; Bruce D Hammock; Robert H Weiss
Journal:  J Cardiovasc Pharmacol       Date:  2008-10       Impact factor: 3.105

9.  Orally bioavailable potent soluble epoxide hydrolase inhibitors.

Authors:  Sung Hee Hwang; Hsing-Ju Tsai; Jun-Yan Liu; Christophe Morisseau; Bruce D Hammock
Journal:  J Med Chem       Date:  2007-07-06       Impact factor: 7.446

Review 10.  Eicosanoids and renal damage in cardiometabolic syndrome.

Authors:  John D Imig
Journal:  Expert Opin Drug Metab Toxicol       Date:  2008-02       Impact factor: 4.481

View more
  3 in total

1.  Exploring the size of the lipophilic unit of the soluble epoxide hydrolase inhibitors.

Authors:  Sandra Codony; Elena Valverde; Rosana Leiva; José Brea; M Isabel Loza; Christophe Morisseau; Bruce D Hammock; Santiago Vázquez
Journal:  Bioorg Med Chem       Date:  2019-08-26       Impact factor: 3.641

2.  In Vitro and In Silico Insights into sEH Inhibitors with Amide-Scaffold from the Leaves of Capsicum chinense Jacq.

Authors:  Jang Hoon Kim; Yeong Deuk Jo; Hyo-Young Kim; Bo-Ram Kim; Bomi Nam
Journal:  Comput Struct Biotechnol J       Date:  2018-10-31       Impact factor: 7.271

Review 3.  Discovery of Soluble Epoxide Hydrolase Inhibitors from Chemical Synthesis and Natural Products.

Authors:  Cheng-Peng Sun; Xin-Yue Zhang; Christophe Morisseau; Sung Hee Hwang; Zhan-Jun Zhang; Bruce D Hammock; Xiao-Chi Ma
Journal:  J Med Chem       Date:  2020-12-28       Impact factor: 7.446

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.